This spring theoretical and practical conferences took place in Baku
and Bishkek and were dedicated to actual issues of use of
neuroprotective drugs in modern pediatrics and child neurology. The
events were devoted to the registration in Azerbaijan and Kyrgyzstan a
new form of original Russian neuroprotector Cortexin, 5 mg - Cortexin
The conferences carried out by GEROPHARM took place with support of
Ministries of Public Health and the Associations of neurologists of
Azerbaijan and Kyrgyzstan.
There were over 200 experts in each town - child neurologists,
pediatricians, therapeutics, neonatologists, epileptologists – which
gathered to hear reports by Russian scientists dedicated to modern
researches in the field of perinatal and pediatric neurology and
Range of topics discussed during the conferences was very wide: the
rehabilitation of children with prenatal damages at an early age,
up-to-dates therapy methods for abstinent syndrome of newborn babies,
optimal therapy for children’s speech development delay, main approaches
to the therapy for acute abnormalities of cerebral circulation emerging
in the pathology of pregnancy and childbirth, as well as new approaches
and methods of modern treatment for actual pathology in pediatrics and
In all reports experts shared Russian experience and progress made in
Cortexin therapy in pediatrics, neurology, therapy and psychiatry.
All talks were successful, but special attention of the audience (
including a number of asked questions) had reports by professors
Vladimir Mitrofanovich Studenikin (Moscow), Olga Vladimirovna
Khaletskaya (Nizhny Novgorod), Vladimir Veniaminovich Kalinin (Moscow),
Tamara Vladimirovna Belousova (Novosibirsk), Irina Mikhaylovna Sutulina (
Kemerovo). Thoroughly studies aspects of pharmacokinetics and
pharmacodynamics of Cortexin including specifics of metabolism in main
pathology of childhood and adequate treatment applied in these cases
formed the basis of for these reports. Active discussion and exchange of
views were continuing long after the closing of the conference.
Nootropic drug Cortexin for children is developed specifically for the treatment of children from the first days of life to 5 years of age. Because of its safety and absence of contraindication, the drug is widely used by child neurologists and pediatricians for treatment for nervous system diseases in Russia, Ukraine, Belarus and Uzbekistan.